Athira Pharma reports FY2022 net loss of $95.6M ($2.53/sh); cash $245.2M; $10M legal settlement

LeonaBio, Inc.

Net loss $95.6M ($2.53 EPS) vs $54.9M ($1.49 EPS) in 2021; R&D spend rose 44% to $61.5M.
Cash, equivalents and investments $245.2M at Dec 31, 2022, vs $319.7M year earlier.
Recorded $10M legal settlement expense for securities class action; subject to court approval.
Targeting LIFT-AD Phase 2/3 enrollment completion mid-2023, topline data early 2024.
ATH-1105 (ALS) IND-enabling studies ongoing; Phase 1 expected in 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.8

LeonaBio, Inc. reported financial results for the year ended December 31, 2022.

Period: the year ended December 31, 2022
Result: reported results

Exact text from the filing

On March 23, 2023, Athira Pharma, Inc. (the “Company”) issued a press release reporting its financial results for the year ended December 31, 2022.

View on SEC.gov

Browse all earnings releases →

LeonaBio, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-009483

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.